Patents Assigned to GEISTLICH PHARMA AG
  • Patent number: 9844555
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Grant
    Filed: March 29, 2017
    Date of Patent: December 19, 2017
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Patent number: 9770538
    Abstract: Skin regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the smooth barrier face. The structure further includes a matrix layer of collagen sponge material adjacent to the fibrous face. The matrix layer of collagen sponge material is resorbed by a body of a subject at a substantially faster rate than the barrier sheet material.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: September 26, 2017
    Assignee: Geistlich Pharma AG
    Inventors: Alan S. Herford, Lothar Schloesser, Peter Geistlich
  • Publication number: 20170196876
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Application
    Filed: March 29, 2017
    Publication date: July 13, 2017
    Applicant: Geistlich Pharma AG
    Inventor: Rolf W. PFIRRMANN
  • Patent number: 9655997
    Abstract: A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 ?m and at least 80% porosity with a pore diameter more than 10 ?m, an onset temperature of 45 to 57° C. and a density in dry state from 50 to 65 mg/cm3. A process for preparing a resilient resorbable chemically crosslinked collagen sponge. A method of using a resilient resorbable chemically crosslinked collagen sponge as an implant in the oral cavity for soft tissue volume augmentation.
    Type: Grant
    Filed: December 15, 2015
    Date of Patent: May 23, 2017
    Assignee: Geistlich Pharma AG
    Inventors: Cornel Imhof, Lothar Schloesser, Niklaus Stiefel, Martin Wuest
  • Patent number: 9624187
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Grant
    Filed: December 3, 2015
    Date of Patent: April 18, 2017
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20160166737
    Abstract: A resilient resorbable chemically crosslinked collagen sponge for promoting soft tissue volume augmentation in the oral region, comprising 60-96% (w/w) collagen and 4-40% (w/w) elastin, which shows by mercury intrusion porosimetry interconnected pores with a median pore diameter between 50 and 90 ?m and at least 80% porosity with a pore diameter more than 10 ?m, an onset temperature of 45 to 57° C. and a density in dry state from 50 to 65 mg/cm3. A process for preparing a resilient resorbable chemically crosslinked collagen sponge. A method of using a resilient resorbable chemically crosslinked collagen sponge as an implant in the oral cavity for soft tissue volume augmentation.
    Type: Application
    Filed: December 15, 2015
    Publication date: June 16, 2016
    Applicant: Geistlich Pharma AG
    Inventors: Cornel IMHOF, Lothar SCHLOESSER, Niklaus STIEFEL, Martin WUEST
  • Publication number: 20160159759
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents. Compositions and methods of using oxathiazin-like compounds and their derivatives are disclosed.
    Type: Application
    Filed: December 3, 2015
    Publication date: June 9, 2016
    Applicant: Geistlich Pharma AG
    Inventor: Rolf W. PFIRRMANN
  • Publication number: 20160144071
    Abstract: The invention relates to: a biomimetic collagen-hydroxyapatite composite material comprising an at least partially fibrous collagen scaffold including mature native collagen fibers possessing triple helicity as shown by Circular Dichroism Spectroscopy, wherein those mature native collagen fibers are at least partially covered with epitactically grown crystals of nanocrystalline hydroxyapatite, whereby the epitactically grown nanocrystals have the same morphology as human bone mineral and the same size as human bone mineral, i.e.
    Type: Application
    Filed: July 18, 2014
    Publication date: May 26, 2016
    Applicant: GEISTLICH PHARMA AG
    Inventor: Michael BUFLER
  • Patent number: 9241943
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.
    Type: Grant
    Filed: June 17, 2013
    Date of Patent: January 26, 2016
    Assignee: Geistlich Pharma AG
    Inventor: Rolf W. Pfirrmann
  • Publication number: 20150182556
    Abstract: The invention provides: —A hydrophilic dehydrated partially purified bone replacement material of natural origin, wherein substantially all non-collagenous organic material is removed while inorganic, porous osseous structure and collagenous structure of natural bone are substantially preserved, characterized in that the bone replacement material contains 0.05 to 1.5 w/w % of at least one of a saccharide or a sugar alcohol, and 0.7 to 5.6 w/w % of a phosphate group selected from the group consisting of phosphate HPO42? and H2PO4?, this phosphate group being part of a physiologically acceptable salt and—a process for preparing a hydrophilic dehydrated partially purified bone replacement material.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 2, 2015
    Applicant: GEISTLICH PHARMA AG
    Inventors: Cornel Imhof, Lothar Schlösser, Birgit Schäfer, Michael Bufler
  • Publication number: 20150182534
    Abstract: New oxathiazin-like compounds and their derivatives are useful as antineoplastic and antimicrobial agents.
    Type: Application
    Filed: June 17, 2013
    Publication date: July 2, 2015
    Applicant: GEISTLICH PHARMA AG
    Inventor: Rolf W. Pfirrmann
  • Patent number: 9066995
    Abstract: The invention relates to: —a porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e.
    Type: Grant
    Filed: December 21, 2011
    Date of Patent: June 30, 2015
    Assignee: GEISTLICH PHARMA AG
    Inventor: Michael Alexander Bufler
  • Patent number: 9028866
    Abstract: It now has been found that oral administration of pharmaceutical agents, including N-methylol transfer agents such as Taurolidine may be used to provide efficacious blood plasma concentration of the agents for treatment of diseases by providing release of the active agent into the duodenum or jejunum of a patient and/or at a pH of about 5.4 to about 6.5. Embodiments of the invention therefore provide oral dosage forms, compositions and methods for administration of pharmaceutical agents to the duodenum or jejunum of a patient, and/or which release at a pH of about 5.4 to about 6.5.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: May 12, 2015
    Assignee: Geistlich Pharma AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Patent number: 8992946
    Abstract: Tissue regeneration or grafting is promoted utilizing a structure including a multi-layer sheet of collagen membrane material which includes a purified collagen barrier sheet material derived from natural collagen-containing tissue, the barrier sheet material including a barrier layer with an outer smooth barrier face and a fibrous face opposite the smooth barrier face. The structure further includes a matrix layer of collagen sponge material adjacent to the fibrous face. The matrix layer of collagen sponge material is resorbed by a body of a subject at a substantially faster rate than the barrier sheet material.
    Type: Grant
    Filed: January 18, 2010
    Date of Patent: March 31, 2015
    Assignee: Geistlich Pharma AG
    Inventors: Peter Geistlich, Lothar Schloesser
  • Patent number: 8852617
    Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: October 7, 2014
    Assignee: Geistlich Pharma AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Patent number: 8852580
    Abstract: An implant for repair of a cartilaginous defect in a subject includes a collagen matrix charged with synovial cells. A method preparing an implant for repair of a cartilaginous defect in a subject includes obtaining a fluid containing synovial cells and charging the synovial cells to the matrix. A device for preparing a cell-charged implant includes a first chamber and a second chamber, the first and second chambers being separated by a membrane and a perforated filter. The membrane is adapted to collect cells from a cell-containing fluid introduced into the first chamber and the perforated filter is adapted to permit passage or diffusion of the fluid through the second chamber. A method for preparing a cell-charged implant utilizes the device.
    Type: Grant
    Filed: September 13, 2012
    Date of Patent: October 7, 2014
    Assignee: Geistlich Pharma AG
    Inventors: Birgit Schaefer, Lothar Schloesser
  • Patent number: 8734524
    Abstract: The invention relates to: —a biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e. a length of 30 to 46 nm and a width of 14 to 22 nm, —a process of preparing the above CAP/HAP bone substitute material comprising the steps of a) preparing a sintered CAP core material, b) immersing the sintered CAP core material in an aqueous solution at a temperature between 10° C. and 50° C.
    Type: Grant
    Filed: June 15, 2010
    Date of Patent: May 27, 2014
    Assignee: Geistlich Pharma AG
    Inventor: Michael Alexander Bufler
  • Publication number: 20130345825
    Abstract: The invention relates to: —a porous biphasic calcium phosphate/hydroxyapatite (CAP/HAP) bone substitute material comprising a sintered CAP core and at least one uniform and closed epitactically grown layer of nanocrystalline HAP deposited on top of the sintered CAP core, whereby the epitactically grown nanocrystals have the same size and morphology as human bone mineral, i.e.
    Type: Application
    Filed: December 21, 2011
    Publication date: December 26, 2013
    Applicant: GEISTLICH PHARMA AG
    Inventor: Michael Alexander Bufler
  • Publication number: 20130189199
    Abstract: A dental care preparation in a form of a toothpaste or tooth gel dentifrice includes an antimicrobial amount of at least one antimicrobial N-methylol transfer agent, and at least one of a fluoride compound or a source of fluoride ions.
    Type: Application
    Filed: September 26, 2011
    Publication date: July 25, 2013
    Applicant: GEISTLICH PHARMA AG
    Inventors: Rolf W. Pfirrmann, Peter Geistlich
  • Patent number: D721803
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: January 27, 2015
    Assignee: Geistlich Pharma AG
    Inventor: Werner F. Dubach